RareBoost Seminar Announcement – Assoc. Prof. Nihat Bugra Agaoglu
We are excited to announce that Dr. Nihat Buğra Ağaoğlu will give a seminar titled “A rare approach to a common entity: Genetic predispostion in cancer” at IBG on September 20, 2024.
About Dr. Agaoglu
Nihat Buğra Ağaoğlu, following his graduation from Marmara University, English School of Medicine, completed his PhD in Medical Genetics at Afyon Kocatepe University. Specializing in cancer genetics and molecular diagnostics, Ağaoğlu continued his work at Ümraniye Training and Research Hospital and later as a research fellow at Dana Farber Cancer Institute at Harvard University Medical School. He currently continues his studies in clinical research and personalized cancer therapy as a senior medical advisor and medical genetics specialist at the Frankfurt Institute of Clinical Cancer Research.
Seminar Abstract
Cancer is one of the most common diseases across the world, but hereditary forms are rare, requiring a tailored approach for each patient and their families. While the genetic predisposition to cancer is widely studied, there is still limited data, and integrating this knowledge into patient care remains a complex and specialized challenge. This presentation aims to explain a unique strategy that emphasizes coordinated decision-making across various specialties.
We facilitate a harmonized collaboration among healthcare providers from various specialties. Our team includes medical doctors (such as medical geneticists, pathologists, oncologists, surgeons, gastroenterologists, obstetrician-gynecologists, and psychiatrists), psychologists, molecular geneticists, and bioinformaticians. By integrating the expertise of each specialty, we create a comprehensive care plan tailored to the patient’s genetic risk and personal values. This approach empowers patients and ensures that all aspects of their care are aligned and optimized.
Moreover, this collaborative model extends beyond patient care, fostering academic productivity. The interdisciplinary nature of our work has led to innovative research opportunities, resulting in publications that contribute to the growing body of knowledge in genetic predisposition and cancer management. Attendees will gain insights into how this strategy enhances patient outcomes and drives academic advancements in this evolving field.